Serum cross-reactive thymosin alpha 1 levels in rats during induction of mammary carcinoma with 7,12-dimethylbenz[a]anthracene: short- and long-term effects.
The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat). Matched control rats were also tested simultaneously. An increase in CRT alpha 1 in DMBA-treated animals was observed within 2 h of DMBA treatment. Thereafter the levels of CRT alpha 1 in the serum of the DMBA-treated rats remained elevated for another 3 weeks prior to declining to control levels. Levels remained stationary until an increase in serum CRT alpha 1 was observed at 9-11 weeks post-DMBA treatment. This correlated with the time when mammary tumors were either palpable or observed. Levels of CRT alpha 1 fell at 13 weeks but remained slightly elevated until sacrifice due to tumor burden at 18 weeks.
Kurl
R N
RN
Program in Clinical Pharmacology, Brown University School of Medicine, Providence, R.I. 02912.
Naylor
P H
PH
Barsoum
A L
AL
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000097:blood* / Q000139:chemically induced; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives* / Q000097:blood
D015127:9,10-Dimethyl-1,2-benzanthracene; D013947:Thymosin; D000077596:Thymalfasin